Debu Tripathy, MD, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer based on the results from the phase III MONALEESA-7 trial.
Debu Tripathy, MD, professor and chair, Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer, based on results from the phase III MONALEESA-7 trial.
Tripathy says physicians are more likely to use CDK4/6 inhibitors now, especially in patients with visceral disease who may be symptomatic. Previously, the concern was that endocrine therapy was not enough and chemotherapy was necessary. Now, data is showing higher response rates.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More